|
| | HR0716 | | LRB101 20252 MST 69792 r |
|
|
1 | | HOUSE RESOLUTION
|
2 | | WHEREAS, Cholangiocarcinoma (bile duct cancer) is a rare |
3 | | form of cancer that originates
from the cells lining the bile |
4 | | ducts that play a key role in digestion; there are three types, |
5 | | Intrahepatic,
extrahepatic, and perihilar; and
|
6 | | WHEREAS, There are approximately 12,000 Americans |
7 | | diagnosed each year in the United States, with numbers
|
8 | | increasing yearly; the mortality rate has increased |
9 | | dramatically in the last decade; and
|
10 | | WHEREAS, Patients are typically diagnosed at a late stage |
11 | | due to no validated early method of detection; symptoms of |
12 | | jaundice, abdominal pain, itchy skin, and weight loss are |
13 | | symptoms that do not usually present till
advanced disease |
14 | | progression; and
|
15 | | WHEREAS, Cholangiocarcinoma is a rare cancer; of the top |
16 | | eight deadliest cancers, seven are rare; rare cancers
have a |
17 | | five-year survival rate under 50%, with the cholangiocarcinoma |
18 | | five-year survival rate being approximately
20%; and |
19 | | WHEREAS, There is currently no cure for |
20 | | cholangiocarcinoma/bile duct cancer; and |